“…Breast AS is an aggressive disease with a poor prognosis . Overall, the outcomes for RAS are thought to be inferior.…”
Section: Introductionmentioning
confidence: 99%
“…Breast AS is an aggressive disease with a poor prognosis. [5][6][7] Overall, the outcomes for RAS are thought to be inferior. Specifically, the 5-year Disease Specific Survival (DSS) for radiation-associated undifferentiated pleomorphic sarcoma (UPS) has been reported to be 44% versus 66%,in case matched sporadic UPS patients.…”
Breast AS is associated with poor survival and high recurrence rates. Prognosis may be mainly determined by its aggressive biology. Referral to tertiary care centers for multimodality treatment is recommended.
“…Breast AS is an aggressive disease with a poor prognosis . Overall, the outcomes for RAS are thought to be inferior.…”
Section: Introductionmentioning
confidence: 99%
“…Breast AS is an aggressive disease with a poor prognosis. [5][6][7] Overall, the outcomes for RAS are thought to be inferior. Specifically, the 5-year Disease Specific Survival (DSS) for radiation-associated undifferentiated pleomorphic sarcoma (UPS) has been reported to be 44% versus 66%,in case matched sporadic UPS patients.…”
Breast AS is associated with poor survival and high recurrence rates. Prognosis may be mainly determined by its aggressive biology. Referral to tertiary care centers for multimodality treatment is recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.